Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Holding ESPR?
Track your performance easily
ESPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $3.40
Previous Close$2.52
Volume3.16M
Average Volume (3M)3.78M
Market Cap
$496.53M
Enterprise Value$620.77M
Total Cash (Recent Filing)$144.72M
Total Debt (Recent Filing)$268.96M
Price to Earnings (P/E)―
Beta3.03
Next Earnings
Feb 27, 2025EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding197,035,171
10 Day Avg. Volume7,049,655
30 Day Avg. Volume3,780,324
Standard Deviation0.27
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.28
Price to Sales (P/S)1.61
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda-11.02
Forecast
1Y Price Target
$7.76Price Target Upside207.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Esperion News
PremiumCompany Announcements
Esperion Therapeutics Sees Significant Revenue Growth in Q3 2024
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe analysis exhibited a 36% relative risk reduction in major adverse limb events following treatment with bempedoic acid compared to placebo.
International ExpansionThe expansion of the BDA franchise to additional international markets is ongoing with regulatory approval for partner Otsuka Pharmaceuticals to market NILEMDO in Taiwan.
Revenue GrowthRevenue continues to grow, posting NEXLETOL/NEXLIZET U.S. product revenue of $31.1 million for the quarter, driven by retail prescription growth of 12% from 2Q24 and 44% from 3Q23.
Bears Say
Financial PerformanceEsperion had a challenging 3Q with total revenues slightly missing expectations and sales of bempedoic acid falling short by 10%.
Geographical Market ImpactDespite progress outside the US, markets like Canada, Australia, and Israel are unlikely to significantly impact Esperion's growth.
Market CompetitionThe primary prevention market for bempedoic acid is underpenetrated, and direct competitors are threatening to launch soon.
---
Ownership Overview
1.00% Insiders
18.28% Mutual Funds
29.52% Other Institutional Investors
41.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $1.16 and its highest was $3.40 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 07, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.025.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -$0.14.
How many shares outstanding does Esperion have?
Esperion has 197,035,170 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -4.525%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Woodline Partners LP. It holds Esperion’s shares valued at 4M.
---
Esperion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.76 (207.94% Upside)
$7.76 (207.94% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q3 2024
0:00 / 0:00
---
ESPR Stock 12 Month Forecast
Average Price Target
$7.76
▲(207.94% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
10/23 ratings generated profit
1 Year Average Return
+42.08%
reiterated a buy rating 8 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +42.08% per trade.
---